Celyad Oncology SA Stock price

Equities

CYAD

BE0974260896

Biotechnology & Medical Research

Real-time Euronext Bruxelles 08:57:50 2024-03-28 am EDT 5-day change 1st Jan Change
0.35 EUR -1.41% Intraday chart for Celyad Oncology SA -2.78% -10.26%
Sales 2021 - Sales 2022 - Capitalization 11.43M 12.36M
Net income 2021 -26M -28.1M Net income 2022 -40M -43.23M EV / Sales 2021 -
Net cash position 2021 27.39M 29.6M Net cash position 2022 12.19M 13.17M EV / Sales 2022 -
P/E ratio 2021
-2.07 x
P/E ratio 2022
-0.28 x
Employees 37
Yield 2021 *
-
Yield 2022
-
Free-Float 92.37%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.41%
1 week-2.78%
Current month-8.14%
1 month-6.91%
3 months-8.85%
6 months-45.31%
Current year-10.26%
More quotes
1 week
0.35
Extreme 0.35
0.37
1 month
0.35
Extreme 0.35
0.40
Current year
0.35
Extreme 0.35
0.47
1 year
0.35
Extreme 0.35
1.28
3 years
0.35
Extreme 0.35
6.26
5 years
0.35
Extreme 0.35
20.45
10 years
0.35
Extreme 0.35
70.95
More quotes
Managers TitleAgeSince
Founder 67 07-07-23
Director of Finance/CFO - 18-12-31
Chief Tech/Sci/R&D Officer - 14-12-31
Members of the board TitleAgeSince
Founder 67 07-07-23
Chairman 59 18-05-06
Director/Board Member - 07-12-31
More insiders
Date Price Change Volume
24-03-28 0.35 -1.41% 8 071
24-03-27 0.355 0.00% 3,795
24-03-26 0.355 +1.43% 4,889
24-03-25 0.35 -1.41% 5,865
24-03-22 0.355 -1.39% 8,769

Real-time Euronext Bruxelles, March 28, 2024 at 08:57 am EDT

More quotes
Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Celyad Oncology SA - Euronext Bruxelles